Seeing Is Believing

Currently out of the existing stock ratings of Tom Smith, 2 are a BUY (100%).
Analyst Tom Smith, currently employed at LEERINK, carries an average stock price target met ratio of 100% that have a potential upside of 22.39% achieved within 59 days.
Tom Smith’s has documented 4 price targets and ratings displayed on 1 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on KROS, Keros Therapeutics at 08-Dec-2020.
Analyst best performing recommendations are on KROS (KEROS THERAPEUTICS ).
The best stock recommendation documented was for KROS (KEROS THERAPEUTICS ) at 5/4/2020. The price target of $42 was fulfilled within 108 days with a profit of $12.98 (44.73%) receiving and performance score of 4.14.
Average potential price target upside
Analyst name
Rating
Rating initiation date
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
Since 31-Jul-2023
$27
$7.8 (40.63%)
$23
2 months 1 days ago
(12-Nov-2025)
0/8 (0%)
$9.53 (54.55%)
Hold
Since 17-Jan-2025
$16
$-3.2 (-16.67%)
$15
2 months 7 days ago
(06-Nov-2025)
3/4 (75%)
$-0.17 (-1.05%)
70
Buy
Since 08-Dec-2023
$26
$6.8 (35.42%)
$26
2 months 24 days ago
(20-Oct-2025)
1/4 (25%)
$10.81 (71.17%)
74
Buy
Since 26-Jul-2023
$26
$6.8 (35.42%)
$41
8 months 1 days ago
(12-May-2025)
1/6 (16.67%)
$12.26 (89.23%)
215
Buy
Since 04-May-2020
$25
$5.8 (30.21%)
$40
8 months 5 days ago
(08-May-2025)
1/14 (7.14%)
$10.98 (78.32%)
113
What Year was the first public recommendation made by Tom Smith?